TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. 詳細を表示
Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540...
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the...
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in...
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.69 | 12.3783965112 | 29.81 | 33.49 | 28.44 | 2486537 | 31.72960057 | CS |
4 | 2.805 | 9.13829613944 | 30.695 | 33.49 | 27.24 | 2823683 | 29.70183118 | CS |
12 | 6.8 | 25.468164794 | 26.7 | 36.84 | 26.15 | 2841711 | 31.38809448 | CS |
26 | 12.85 | 62.2276029056 | 20.65 | 36.84 | 16.8901 | 3271016 | 26.26405689 | CS |
52 | 17.67 | 111.623499684 | 15.83 | 36.84 | 12.84 | 3255154 | 21.35186906 | CS |
156 | 23.61 | 238.725985844 | 9.89 | 36.84 | 3.48 | 3860867 | 15.23285221 | CS |
260 | 19.25 | 135.087719298 | 14.25 | 56.74 | 3.48 | 3014992 | 18.04086472 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約